Filing Flows › Altimmune (ALT) › Q2 2025
Altimmune (ALT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 12, 2025
Altimmune (ALT) reported revenue of $5K for the second quarter 2025 (Q2 2025), 0% from a year earlier and 0% from the quarter before.
Altimmune, Q2 2025: revenue $5K (0% year over year), net loss $22.1M, operating cash flow −$19.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $5K | 0% | 0% |
| Operating profit | −$22.9M | — | — |
| Net earnings | −$22.1M | — | — |
| Operating cash flow | −$19.4M | — | — |
What changed
Revenue was $5K in Q2 2025, roughly flat year over year and roughly flat from the previous quarter.
Operating costs exceeded revenue by $22.9M, an operating margin of -458440.0%. Total costs fell 14% while revenue was flat. The quarter ended with a net loss of $22.1M, wider than the previous quarter's $19.6M loss.
Operating cash flow was −$19.4M. Non-cash charges added back $30K of depreciation and $3.6M of share-based compensation.
Questions
What was Altimmune's revenue in the second quarter 2025?
Altimmune (ALT) reported revenue of $5K for the second quarter 2025 (Q2 2025), 0% from a year earlier and 0% from the quarter before.
Source: Altimmune 10-Q on SEC EDGAR.